{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:54:49Z","timestamp":1768290889345,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.neurol.2021.01.015","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:57:15Z","timestamp":1624507035000},"page":"1082-1089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mini review \u2013 The role of Glucocerebrosidase and Progranulin as possible targets in the treatment of Parkinson's disease"],"prefix":"10.1016","volume":"177","author":[{"given":"P.S.","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-1037","authenticated-orcid":false,"given":"P.P.","family":"Kale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2021.01.015_bib0355","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuroscience.2018.09.017","article-title":"Proteomic Profiling of Exosomal Proteins for Blood-based Biomarkers in Parkinson's Disease","volume":"392","author":"Kitamura","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurol.2021.01.015_bib0360","doi-asserted-by":"crossref","first-page":"E5815","DOI":"10.1073\/pnas.1802179115","article-title":"Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease","volume":"115","author":"Ren","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2021.01.015_bib0365","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1503\/cmaj.151179","article-title":"An update on the diagnosis and treatment of Parkinson disease","volume":"188","author":"Rizek","year":"2016","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.neurol.2021.01.015_bib0370","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cell.2011.06.031","article-title":"A feedforward loop links Gaucher and Parkinson's diseases?","volume":"146","author":"Cookson","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2021.01.015_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1073858417748875","article-title":"Glucocerebrosidase and Parkinson Disease: molecular, clinical, and therapeutic implications","volume":"24","author":"Balestrino","year":"2018","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neurol.2021.01.015_bib0380","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","article-title":"Acid ceramidase inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function","volume":"27","author":"Kim","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurol.2021.01.015_bib0385","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14728222.2018.1487951","article-title":"Progranulin as a therapeutic target for dementia","volume":"22","author":"Galimberti","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.neurol.2021.01.015_bib0390","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11910-018-0860-4","article-title":"GBA-Associated Parkinson's Disease and Other Synucleinopathies","volume":"18","author":"Gan-Or","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.neurol.2021.01.015_bib0395","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2011.10.003","article-title":"Progranulin: a growth factor, a novel TNFR ligand and a drug target","volume":"133","author":"Liu","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurol.2021.01.015_bib0400","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"NIH Public Access","volume":"361","author":"Sidransky","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2021.01.015_bib0405","first-page":"937","article-title":"Parkinsonism among Gaucher disease carriers","author":"Schiffmann","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.neurol.2021.01.015_bib0410","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mds.25248","article-title":"The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease","volume":"28","author":"Duran","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2021.01.015_bib0415","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","article-title":"Glucocerebrosidase mutations in subjects with parkinsonism","volume":"81","author":"Lwin","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.neurol.2021.01.015_bib0420","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ymgme.2007.03.004","article-title":"Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease","volume":"91","author":"Ziegler","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.neurol.2021.01.015_bib0425","doi-asserted-by":"crossref","unstructured":"Moraitou M, Hadjigeorgiou G, Monopolis I, Dardiotis E, Bozi M, Vassilatis D, et al. (-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Mol Genet Metab n.d.;104:149-52. https:\/\/doi.org\/10.1016\/j.ymgme.2011.06.015.","DOI":"10.1016\/j.ymgme.2011.06.015"},{"key":"10.1016\/j.neurol.2021.01.015_bib0430","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/jnnp-2019-320394","article-title":"Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study","volume":"90","author":"Avenali","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2021.01.015_bib0435","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamem.2006.06.009","article-title":"Sphingolipid metabolism in neural cells","volume":"1758","author":"van Echten-Deckert","year":"2006","journal-title":"Biochim Biophys Acta - Biomembr"},{"key":"10.1016\/j.neurol.2021.01.015_bib0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.27583","article-title":"Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine","volume":"34","author":"Blandini","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2021.01.015_bib0445","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2021.01.015_bib0450","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuint.2017.12.014","article-title":"Pathological role of lipid interaction with \u03b1-synuclein in Parkinson's disease","volume":"119","author":"Suzuki","year":"2018","journal-title":"Neurochem Int"},{"key":"10.1016\/j.neurol.2021.01.015_bib0455","doi-asserted-by":"crossref","first-page":"28080","DOI":"10.1074\/jbc.M111.237859","article-title":"\u03b1-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases","volume":"286","author":"Yap","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurol.2021.01.015_bib0460","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neurol.2021.01.015_bib0465","first-page":"540","article-title":"Glucocerebrosidase and Parkinson Disease: molecular, clinical, and therapeutic implications","volume":"24","author":"Balestrino","year":"2018","journal-title":"Neurosci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0962-8924(99)01694-3","article-title":"Ceramide in the eukaryotic stress response","volume":"10","author":"Hannun","year":"2000","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.plipres.2011.11.001","article-title":"Chain length-specific properties of ceramides","volume":"51","author":"Gr\u00f6sch","year":"2012","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.neurol.2021.01.015_bib0480","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson's disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.01.015_bib0485","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mds.25729","article-title":"Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease","volume":"29","author":"Abbott","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2021.01.015_bib0490","doi-asserted-by":"crossref","first-page":"e1000027","DOI":"10.1371\/journal.pgen.1000027","article-title":"C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging","volume":"4","author":"van Ham","year":"2008","journal-title":"PLoS Genet"},{"key":"10.1016\/j.neurol.2021.01.015_bib0495","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00018-012-1038-x","article-title":"Ceramide function in the brain: when a slight tilt is enough","volume":"70","author":"Mencarelli","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2019.00330","article-title":"Ceramides in Parkinson\u2019s Disease: from recent evidence to new hypotheses","volume":"13","author":"Plotegher","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0505","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cellsig.2007.12.006","article-title":"The sphingolipid salvage pathway in ceramide metabolism and signaling","volume":"20","author":"Kitatani","year":"2008","journal-title":"Cell Signal"},{"key":"10.1016\/j.neurol.2021.01.015_bib0510","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1749-6632.1998.tb09661.x","article-title":"Metabolic fate of exogenous sphingosine in neuroblastoma neuro2A cells. Dose-dependence and biological effects","volume":"845","author":"Riboni","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0515","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0014-5793(98)00325-1","article-title":"Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue","volume":"426","author":"Chatelut","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.neurol.2021.01.015_bib0520","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00018-012-1038-x","article-title":"Ceramide function in the brain: when a slight tilt is enough","volume":"70","author":"Mencarelli","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0525","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamem.2006.06.009","article-title":"Sphingolipid metabolism in neural cells","volume":"1758","author":"van Echten-Deckert","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.neurol.2021.01.015_bib0530","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","article-title":"Insights into the structural biology of Gaucher disease","volume":"298","author":"Smith","year":"2017","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0535","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0540","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine Promotes \u03b1-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0545","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fneur.2020.00437","article-title":"Exploring Sphingolipid Implications in Neurodegeneration","volume":"11","author":"Alessenko","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0550","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ajhg.2012.04.021","article-title":"Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage","volume":"90","author":"Smith","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.neurol.2021.01.015_bib0555","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1093\/hmg\/ddx364","article-title":"Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients","volume":"26","author":"Valdez","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurol.2021.01.015_bib0560","doi-asserted-by":"crossref","first-page":"e0212382","DOI":"10.1371\/journal.pone.0212382","article-title":"Progranulin deficiency leads to reduced glucocerebrosidase activity","volume":"14","author":"Zhou","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2021.01.015_bib0565","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.08.004","article-title":"Association Between Progranulin and Gaucher Disease","volume":"11","author":"Jian","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurol.2021.01.015_bib0570","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-014-0078-x","article-title":"Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice","volume":"2","author":"Tanaka","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurol.2021.01.015_bib0575","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1177\/1352458511406164","article-title":"Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis","volume":"17","author":"Vercellino","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2021.01.015_bib0580","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","article-title":"Advances in understanding the molecular basis of frontotemporal dementia","volume":"8","author":"Rademakers","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0585","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.01.015_bib0590","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A New Glucocerebrosidase Chaperone Reduces \u03b1-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2020.00271","article-title":"Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease","volume":"8","author":"Han","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci9020030","article-title":"Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency","volume":"9","author":"Gatto","year":"2019","journal-title":"Brain Sci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0605","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0610","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J"},{"key":"10.1016\/j.neurol.2021.01.015_bib0615","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2021.01.015_bib0620","doi-asserted-by":"crossref","first-page":"31380","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2021.01.015_bib0625","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy","volume":"11","author":"Richter","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2021.01.015_bib0630","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid \u03b2-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurol.2021.01.015_bib0635","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.neurol.2021.01.015_bib0640","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurol.2021.01.015_bib0645","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nbd.2009.07.019","article-title":"Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo","volume":"36","author":"Faraco","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2021.01.015_bib0650","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12035-009-8067-y","article-title":"Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors","volume":"40","author":"Thomas","year":"2009","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0655","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1073\/pnas.1221046110","article-title":"Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2021.01.015_bib0660","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/oxfordjournals.jbchem.a124584","article-title":"The synthetic pathway for glucosylsphingosine in cultured fibroblasts","volume":"116","author":"Yamaguchi","year":"1994","journal-title":"J Biochem"},{"key":"10.1016\/j.neurol.2021.01.015_bib0665","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/srep01035","article-title":"Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity","volume":"3","author":"Realini","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2021.01.015_bib0670","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1523\/JNEUROSCI.5757-10.2011","article-title":"Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase","volume":"31","author":"Capell","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2017.06.010","article-title":"Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia","volume":"24","author":"She","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.neurol.2021.01.015_bib0680","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2016.03.001","article-title":"Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients","volume":"42","author":"Almeida","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2021.01.015_bib0685","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/hmg\/ddt534","article-title":"Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency","volume":"23","author":"Lee","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurol.2021.01.015_bib0690","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/glycob\/cwu187","article-title":"Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids","volume":"25","author":"Alam","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.neurol.2021.01.015_bib0695","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models","volume":"114","author":"Sardi","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurol.2021.01.015_bib0700","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721005671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721005671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:42:53Z","timestamp":1758519773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378721005671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0035378721005671"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2021.01.015","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mini review \u2013 The role of Glucocerebrosidase and Progranulin as possible targets in the treatment of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2021.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}